Published 1 day ago

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - Pipelinereview

Summary by Pipelinereview

Allogeneic, TSCM-rich dual CAR-T for the treatment of hematologic malignancies, including multiple myeloma Nomination triggers $15 million milestone payment to Poseida, extending cash runway into early 2026 SAN DIEGO, CA, USA I October 17, 2024 I Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and …

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated20 hours agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - Pipelinereview

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics